Multiple Myeloma

Disparities in hematopoietic stem cell transplantation utilization for blood cancers have narrowed over time but still persist, according to study results.

Decreasing the amount of dexamethasone that individuals with newly diagnosed multiple myeloma received did not affect survival, according to a secondary analysis of completed clinical trials.

The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.

A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses how she approaches putting together a treatment plan for a patient with multiple myeloma.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses how multiple myeloma awareness can be increased among the general public.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the major areas of unmet need in multiple myeloma treatment.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses some of the new treatments in the pipeline for multiple myeloma.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the mysteries still surrounding who is most likely to develop multiple myeloma.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the new wave of novel therapeutics on the market to treat multiple myeloma.